New Drug Developments Target Genetic Heart Risk Factor
By Editor • August 26, 2026 • 1 min read
As heart disease remains a pressing concern, drugmakers are focusing on Lp(a), a genetic risk factor difficult to manage through lifestyle changes. With 20% of individuals affected, pharmaceutical companies like Novartis are advancing late-stage trials for treatments aimed at lowering Lp(a) levels, tapping into a significant market opportunity.
Source: www.statnews.com
#cardiovascular #drug development #heart disease #Lp(a) #Novartis
